bimatoprost
Lumigan · ATC code S01EE03
Brand names: Lumigan, Bima-Vision Sine, Bimato-Vision, Bimatoprost Sandoz, Bimatoprost Stada, Elymbus, Iricryn, Amiriox, Bimatoprost -, Bimatroprost Al, Visuplain, Bematorin, Bimagan, Bimapress, Bimatocare % …
- Key facts
- Active substance
- bimatoprost
- ATC code
- S01EE03
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- LUMIGAN 0.1 mg/ml eye drops, solution · LUMIGAN 0.3 mg/ml eye drops, solution · LUMIGAN 0.3 mg/ml eye drops, solution, in single-dose container
- Marketing authorisation holder
- AbbVie Deutschland GmbH & Co. KG
- Information as of
- 2026-10-27
Key facts
Bimatoprost is a prostaglandin analogue eye drop used to reduce elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults.
What it is used for
- Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults, as monotherapy or adjunctive to beta-blockers
Dosing
- Lumigan 0.1 mg/ml and 0.3 mg/ml: one drop in the affected eye(s) once daily in the evening
- Not more than once daily, as more frequent use may lessen the pressure-lowering effect
- Separate different topical eye medicines by at least 5 minutes
- Not studied in renal or moderate to severe hepatic impairment: use with caution
- Children and adolescents: safety and efficacy not established
Contraindications
- Hypersensitivity to the active substance or any excipient
- Suspected previous adverse reaction to benzalkonium chloride that led to discontinuation (Lumigan 0.1 mg/ml and 0.3 mg/ml)
Important warnings
- Prostaglandin analogue periorbitopathy and increased iris pigmentation may occur, some permanent; differences between eyes if only one is treated
- Cystoid macular oedema uncommonly reported; caution with risk factors (e.g. aphakia, pseudophakia with torn posterior capsule)
- Caution with prior significant ocular viral infections (e.g. herpes simplex) or uveitis/iritis
- Hair growth may occur on skin repeatedly in contact with the solution
Side effects
- Lumigan 0.1 mg/ml: most frequent conjunctival hyperaemia (29%), mostly mild
- Lumigan 0.3 mg/ml: in the first year eyelash growth (up to 45%), conjunctival hyperaemia (up to 44%) and ocular pruritus (up to 14%)
- Prostaglandin analogue periorbitopathy is also very common; headache uncommon
Interactions
- No interaction studies; none anticipated given very low systemic concentrations
- Use with other prostaglandin analogues may reduce the pressure-lowering effect
Pregnancy and breastfeeding
- Should not be used during pregnancy unless clearly necessary
- Unknown whether excreted in human milk; decide between stopping breast-feeding or therapy based on benefit
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- LumiganAbbVie Deutschland GmbH & Co. KG · EMEA/H/C/000391
Source: European Medicines Agency (EMA), product information
Austria
- Bima-Vision SineOmnivision Gmbh · 1 register entry
- Bimato-VisionOmnivision Gmbh · 1 register entry
- Bimatoprost SandozSandoz Gmbh · 1 register entry
- Bimatoprost StadaStada Arzneimittel Gmbh · 1 register entry
- ElymbusLaboratoires Thea · 1 register entry
- IricrynTrb Chemedica (Austria) Gmbh · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Germany
- AmirioxSifi S.P.A. · 1 register entry
- Bimato-VisionOmnivision Gmbh · 2 register entries
- Bimatoprost -1 A Pharma Gmbh, Micro Labs Gmbh, Ntc Srl, Axunio Pharma Gmbh, Pharma Stulln Gmbh, Hexal Ag, Aliud Pharma Gmbh · 10 register entries
- Bimatroprost AlAliud Pharma Gmbh · 1 register entry
- ElymbusLaboratoires Thea · 1 register entry
- IricrynTrb Chemedica Ag · 1 register entry
- VisuplainVisufarma Spa · 1 register entry
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- BematorinDEVA HOLDİNG A.Ş. · 2 register entries
- BimaganWORLD MEDICINE İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- BimapressROMPHARM İLAÇ SAN. VE TİC. LTD. ŞTİ. · 2 register entries
- Bimatocare %SABA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- Lumaglo %VEM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
- Lumigan RC %ABBVİE TIBBİ İLAÇLAR SAN. VE TİC. LTD. ŞTİ. · 1 register entry
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 26 more European countries
- Belgium
- Bimatoprost Eg, Elymbus
- Bulgaria
- Бимаган, Биматопрост Абр, Визибим, Елимбус, Торпида
- Croatia
- Elymbus
- Cyprus
- Bimatoprost Pharmathen, Birmost, Elymbus
- Czechia
- Bimatoprost Farmaprojects, Bimatoprost Olikla, Bimatoprost Stada, Bimican, Elymbus, Vizibim
- Denmark
- Bimatoprost "hexal", Bimatoprost "stada", Bimatoprost Pharmathen, Bimatoprost Stada, Elymbus, Iricryn, Vizibim
- Estonia
- Elymbus
- Finland
- Bimatoprost, Elymbus, Iricryn
- France
- Amiriox, Bimatoprost, Bimatorpost Medipha Sante, Elumibus, Iricryn
- Greece
- Birmost, Dacrysan, Elymbus
- Iceland
- Bimatoprost, Elymbus, Lumigan
- Ireland
- Elymbus, Eyreida, Iricryn
- Italy
- Amiriox, Bialviz, Bimadoc, Bimanext, Bimatoprost Eg, Bimatoprost Mylan, Bimatoprost Pharmathen, Bimatoprost Sandoz Gmbh, Brinus, Elymbus, Visuplain
- Latvia
- Bimican, Bimifre, Elymbus, Iricryn
- Liechtenstein
- Lumigan
- Lithuania
- Bimican, Bimifree, Elymbus
- Luxembourg
- Bimatoprost Eg, Bimatoprost Medicom, Elymbus
- Netherlands
- Bimagan, Bimato-Vision, Bimatoprost Axunio, Bimatoprost Brown & Burk, Bimatoprost Cf, Bimatoprost Idifarma Desarrollo Farmacéutico, Bimatoprost Ntc, Bimatoprost Sandoz, Bimatoprost Stulln, Bimatoprost Viatris, Bimeox, Elymbus, Ganmono Conserveermiddelvrij
- Norway
- Bimaprez, Bimatoprost Hexal, Elymbus, Iricryn, Lumigan
- Poland
- Bimican, Bimifree, Elymbus, Vizibim
- Portugal
- Amiriox, Bimatoprost Stulln, Bimeox, Birmost, Elymbus, Iricryn
- Romania
- Amiriox, Bimagan, Elymbus
- Slovakia
- Bimatoprost Olikla, Elymbus, Vizibim
- Slovenia
- Elymbus
- Spain
- Amiriox, Bamixol, Bimeox, Bimi, Elymbus, Visuplain, Zimed
- Sweden
- Bimaprez, Bimatoprost, Elymbus, Iricryn
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Lumigan – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/lumigan-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.